SHIONOGI-USA
23.11.2022 09:47:36 CET | Business Wire | Press release
SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; hereafter "Shionogi"), officially opened the doors to its new European Headquarters in Herengracht, Amsterdam, today, marking the next stage of growth for the Japanese pharmaceutical company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005494/en/
Shionogi Amsterdam European Headquarters in Herengracht (Credit: Shionogi)
The opening ceremony was conducted by His Excellency, Mr Hidehisa Horinouchi, Ambassador of Japan to the Netherlands, in the presence of Shionogi, Senior Executive Officer, Senior Vice President of Supply Supervisory Unit and Global Business Division, Dr. Koji Hanasaki. Others in attendance included guests from the Netherlands Foreign Investment Agency and Holland Bio, alongside the Shionogi Europe Executive Committee and all current employees based in the new office.
European CEO, Huw Tippett said: “The decision to open our new headquarters in Amsterdam was an easy one for the business. Amsterdam is a great city with a thriving life science community across both biopharmaceuticals and medical technology. It is renowned for its leading knowledge institutions, public-private partnerships, strategic location and of course the presence of key regulatory bodies such as the European Medicines Agency. The new office adds further strength to Shionogi’s European capabilities, as we continue on our ambitious growth journey”.
Shionogi has a long heritage in the development and marketing of anti-infectious disease treatments, as well as therapeutic areas such as haematology, women’s health, pain and central nervous system disorders. The office opening event coincides with World Anti-Microbial Resistance Awareness Week (WAAW) which Shionogi marked on Friday 18th November by participating in the World Health Organisation’s Go Blue campaign and lighting up the new Amsterdam office with blue lights.
Dr. Hanasaki said, “At Shionogi we are proud to have delivered treatments in areas of major public health concern and are steadfast in our pursuit to find even better solutions using our advanced scientific know-how, talented people and passion. A strong presence in Europe is vital to support our global vision of building innovation platforms to shape the future of healthcare, and I am delighted to be visiting the new office and forging new connections with the Netherlands business and science community”.
-ENDS-
For images or requests for interview contact Jo Taylor Executive Director, Corporate and Government Affairs on +44 (0)20 3053 4200
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company based in Japan dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company has discovered and developed novel medicines for HIV, influenza and antimicrobial resistance and currently markets products in several therapeutic areas including anti-infectives. Other therapeutic areas, and the focus of the company’s pipeline, include CNS/psychoneurological diseases, oncology and pain.
Shionogi B.V. is a private limited liability company formed under Dutch law, trading as Shionogi Europe. Shionogi B.V. is registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180 and our registered address is Herengracht 464, 1017CA., please visit www.shionogi.eu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005494/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CapVest Completes Majority Acquisition of Stada31.3.2026 13:10:00 CEST | Press release
CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty Pharmaceuticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331987319/en/ Building on strong 2025 results, the completion of the transaction will allow the CapVest and STADA teams to jointly progress their ambitious plans to accelerate the growth of the company globally and deploying capital towards pursuing organic growth and new strategic acquisitions. Currently employing close to 12,000 people worldwide, STADA is a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. The Company recently announced record revenues of €4.3 billion, a 6% incr
GetVocal Introduces Control Center to Help Enterprises Scale AI Across 90 Percent Plus of Customer Conversations31.3.2026 13:00:00 CEST | Press release
New governance layer enables human-in-the-loop operations, allowing AI to handle customer interactions while humans stay in control of critical decisions GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the launch of its Control Center, a human-AI operations interface designed to help enterprises scale customer experience (CX) automation while maintaining trust, compliance, and full human oversight. As organizations expand AI from simple requests to complex customer journeys, they face a dual operational challenge: if AI acts alone, risk increases; but if humans review everything, automation doesn’t scale. GetVocal’s Control Center solves this challenge by introducing a governance layer for real-time two-way human-AI collaboration. In this hybrid workforce model, AI resolves most customer interactions independently, and humans step in only when judgment, validation, or exception handling is required. The Control Center is
Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code31.3.2026 13:00:00 CEST | Press release
New AI-platform enables non-tech teams to build fully functional, secure applications for real business operations, not just prototypes Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need. This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay. Softr’s new platform was built to brid
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform31.3.2026 12:00:00 CEST | Press release
Round Led by Collaborative Fund with Participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Cristiano Ronaldo, LeBron James, Rory McIlroy WHOOP, the human performance company, today announced it has raised $575 million in Series G funding at a $10.1 billion valuation, advancing its global expansion and long-term vision for personalized health. The round was led by Collaborative Fund and includes global participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Macquarie Capital (entities administered by Macquarie Capital), Glade Brook, B-Flexion, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures, and Bullhound Capital alongside a group of prominent global athletes and individual investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331399622/en/ WHOOP Raises $575 Million at $10.1 B
Interactive Brokers Launches Crypto-Asset Trading for Individual Investors in the European Economic Area31.3.2026 11:00:00 CEST | Press release
Eligible clients can now trade 11 popular crypto-assets including Bitcoin and Ethereum alongside stocks, options, futures, and more, all from a single, integrated platform Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of crypto-asset trading for eligible individual investors in the EEA through Interactive Brokers Ireland Limited, which is an authorised crypto-asset service provider in the EEA. Many European investors face challenges managing multiple crypto apps, understanding unclear fees, or navigating security concerns. Interactive Brokers now offers a solution. Starting today, eligible individual investors in the EEA can trade 11 leading crypto-assets directly on the same platform they already use for stocks, options, futures, currencies, bonds, and mutual funds. This integrated approach gives clients a unified view of their entire portfolio. With one login, they can manage both traditional and crypto-assets, backed by the control, low p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom